Treatment of Autoimmune Hepatitis
- PMID: 37945162
- DOI: 10.1016/j.cld.2023.07.001
Treatment of Autoimmune Hepatitis
Abstract
The goal of autoimmune hepatitis treatment is to achieve clinical and biochemical remission, which is associated with significantly improved outcomes. Induction treatment with corticosteroids and the subsequent addition of steroid-sparing therapy with gradual tapering of corticosteroids remains the standard of care. Several alternatives to azathioprine and second-line agents, such as mycophenolate mofetil, tacrolimus, cyclosporine, sirolimus, or rituximab, have been evaluated in those with intolerance or inadequate response to standard-of-care therapy. Treatment withdrawal is achievable in less than 20% of patients after 2 years of sustained remission. Liver transplantation should be considered in those with progressive liver disease or those with complications such as hepatocellular carcinoma.
Keywords: Autoimmune hepatitis; Biochemical remission; Immunosuppression; Liver transplant; Recurrent autoimmune hepatitis; Treatment failure.
Copyright © 2023 Elsevier Inc. All rights reserved.
Similar articles
-
Current and prospective pharmacotherapy for autoimmune hepatitis.Expert Opin Pharmacother. 2014 Aug;15(12):1715-36. doi: 10.1517/14656566.2014.931938. Epub 2014 Jun 25. Expert Opin Pharmacother. 2014. PMID: 24961409 Review.
-
Everolimus treatment for patients with autoimmune hepatitis and poor response to standard therapy and drug alternatives in use.Scand J Gastroenterol. 2015 Aug;50(8):1025-31. doi: 10.3109/00365521.2014.998271. Epub 2015 Apr 10. Scand J Gastroenterol. 2015. PMID: 25862144
-
Histological changes after the use of mycophenolate mofetil in autoimmune hepatitis.Hum Pathol. 2004 Apr;35(4):509-12. doi: 10.1016/j.humpath.2003.10.017. Hum Pathol. 2004. PMID: 15116334
-
The role of mycophenolate mofetil in the management of autoimmune hepatitis and overlap syndromes.Aliment Pharmacol Ther. 2011 Aug;34(3):335-43. doi: 10.1111/j.1365-2036.2011.04727.x. Epub 2011 Jun 12. Aliment Pharmacol Ther. 2011. PMID: 21668459
-
Current and novel immunosuppressive therapy for autoimmune hepatitis.Hepatology. 2002 Jan;35(1):7-13. doi: 10.1053/jhep.2002.30991. Hepatology. 2002. PMID: 11786954 Review.
Cited by
-
Increased Risk of Non-Hodgkin Lymphoma in Autoimmune Hepatitis: A Large Retrospective Cohort Study.J Clin Med. 2024 Oct 20;13(20):6258. doi: 10.3390/jcm13206258. J Clin Med. 2024. PMID: 39458208 Free PMC article.
-
Inflammatory bowel disease and risk of autoimmune hepatitis: A univariable and multivariable Mendelian randomization study.PLoS One. 2024 Jun 7;19(6):e0305220. doi: 10.1371/journal.pone.0305220. eCollection 2024. PLoS One. 2024. PMID: 38848323 Free PMC article.
-
Unusual Causes of Jaundice: A Diagnostic Challenge.Cureus. 2023 Nov 30;15(11):e49760. doi: 10.7759/cureus.49760. eCollection 2023 Nov. Cureus. 2023. PMID: 38161852 Free PMC article.
-
Succinic Acid Ameliorates Concanavalin A-Induced Hepatitis by Altering the Inflammatory Microenvironment and Expression of BCL-2 Family Proteins.Inflammation. 2024 Dec;47(6):2000-2012. doi: 10.1007/s10753-024-02021-6. Epub 2024 Apr 13. Inflammation. 2024. PMID: 38613638
-
Exosome-Modified AAV Gene Therapy Attenuates Autoimmune Hepatitis via Enhanced Regulatory T Cell Targeting and Immune Modulation.Microorganisms. 2025 Apr 4;13(4):823. doi: 10.3390/microorganisms13040823. Microorganisms. 2025. PMID: 40284659 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources